D'Haens GR - Search Results

1

Golimumab for moderate to severe ulcerative colitis.

Strik AS, Berends SE, Mathôt RA, D'Haens GR, Löwenberg M. Strik AS, et al. Expert Rev Gastroenterol Hepatol. 2017 May;11(5):401-406. doi: 10.1080/17474124.2017.1303376. Epub 2017 Mar 9. Expert Rev Gastroenterol Hepatol. 2017. PMID: 28276288 Review.

2

Pericholangitis and sclerosing cholangitis are risk factors for dysplasia and cancer in ulcerative colitis.

D'Haens GR, Lashner BA, Hanauer SB. D'Haens GR, et al. Am J Gastroenterol. 1993 Aug;88(8):1174-8. Am J Gastroenterol. 1993. PMID: 8338083

3

Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis.

D'Haens G, Lemmens L, Geboes K, Vandeputte L, Van Acker F, Mortelmans L, Peeters M, Vermeire S, Penninckx F, Nevens F, Hiele M, Rutgeerts P. D'Haens G, et al. Gastroenterology. 2001 May;120(6):1323-9. doi: 10.1053/gast.2001.23983. Gastroenterology. 2001. PMID: 11313301 Clinical Trial.

4

The role of aminosalicylates in the treatment of ulcerative colitis.

Van Assche G, Baert F, De Reuck M, De Vos M, De Wit O, Hoang P, Louis E, Mana F, Pelckmans P, Rutgeerts P, Van Gossum A, D'Haens G. Van Assche G, et al. Acta Gastroenterol Belg. 2002 Oct-Dec;65(4):196-9. Acta Gastroenterol Belg. 2002. PMID: 12619425

5

Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis.

Van Assche G, D'Haens G, Noman M, Vermeire S, Hiele M, Asnong K, Arts J, D'Hoore A, Penninckx F, Rutgeerts P. Van Assche G, et al. Gastroenterology. 2003 Oct;125(4):1025-31. doi: 10.1016/s0016-5085(03)01214-9. Gastroenterology. 2003. PMID: 14517785 Clinical Trial.

6

A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis.

Tilg H, Vogelsang H, Ludwiczek O, Lochs H, Kaser A, Colombel JF, Ulmer H, Rutgeerts P, Krüger S, Cortot A, D'Haens G, Harrer M, Gasche C, Wrba F, Kuhn I, Reinisch W. Tilg H, et al. Gut. 2003 Dec;52(12):1728-33. doi: 10.1136/gut.52.12.1728. Gut. 2003. PMID: 14633951 Free PMC article. Clinical Trial.

7

Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease.

Hommes DW, Mikhajlova TL, Stoinov S, Stimac D, Vucelic B, Lonovics J, Zákuciová M, D'Haens G, Van Assche G, Ba S, Lee S, Pearce T. Hommes DW, et al. Gut. 2006 Aug;55(8):1131-7. doi: 10.1136/gut.2005.079392. Epub 2006 Feb 28. Gut. 2006. PMID: 16507585 Free PMC article. Clinical Trial.

8

Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study.

D'Haens G, Hommes D, Engels L, Baert F, van der Waaij L, Connor P, Ramage J, Dewit O, Palmen M, Stephenson D, Joseph R. D'Haens G, et al. Aliment Pharmacol Ther. 2006 Oct 1;24(7):1087-97. doi: 10.1111/j.1365-2036.2006.03082.x. Aliment Pharmacol Ther. 2006. PMID: 16984503 Free article. Clinical Trial.

9

Advances in biologic therapy for ulcerative colitis and Crohn's disease.

D'Haens G, Daperno M. D'Haens G, et al. Curr Gastroenterol Rep. 2006 Dec;8(6):506-12. doi: 10.1007/s11894-006-0041-5. Curr Gastroenterol Rep. 2006. PMID: 17105690 Review.

10

Optimizing biologic therapies for inflammatory bowel disease (ulcerative colitis and Crohn's disease).

Ferrante M, D'Haens G, Rutgeerts P, Vermeire S, Van Assche G. Ferrante M, et al. Curr Gastroenterol Rep. 2009 Dec;11(6):504-8. doi: 10.1007/s11894-009-0076-5. Curr Gastroenterol Rep. 2009. PMID: 19903427 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

600 results

Search Page

Filters